Difference between revisions of "Daratumumab and vorhyaluronidase (Darzquro)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 8: | Line 8: | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2021-03-23: Newly indicated for the treatment of [[multiple myeloma]]. | *2021-03-23: Newly indicated for the treatment of [[multiple myeloma]]. | ||
| − | *2021-08-25: | + | *2021-08-25: New indication and a new dosage for the treatment of [[Light-chain (AL) amyloidosis|systemic AL amyloidosis]]. |
==Also known as== | ==Also known as== | ||
| − | *'''Generic name:''' | + | *'''Generic name:''' daratumumab and vorhyaluronidase alfa |
*'''Brand name:''' Darzquro | *'''Brand name:''' Darzquro | ||
Latest revision as of 18:34, 14 August 2023
General information
Class/mechanism: Anti-CD38 antibody, human monoclonal IgG1 kappa. Daratumumab binds to CD38 and causes apoptosis in CD38-expressing cells via Fc mediated cross-linking, complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). CD38 is present on the cell surface of multiple myeloma (MM), plasma leukemia, and natural killer (NK) cells.
Diseases for which it is used
History of changes in PMDA indication
- 2021-03-23: Newly indicated for the treatment of multiple myeloma.
- 2021-08-25: New indication and a new dosage for the treatment of systemic AL amyloidosis.
Also known as
- Generic name: daratumumab and vorhyaluronidase alfa
- Brand name: Darzquro